| scholarly article | Q13442814 |
| consensus development conference proceedings | Q58900768 |
| P50 | author | Tom Leslie | Q55644865 |
| Arnauld Villers | Q56531008 | ||
| Caroline Moore | Q62606989 | ||
| Lucy A Simmons | Q63967544 | ||
| Mark Emberton | Q63968187 | ||
| Peter A Pinto | Q90059716 | ||
| Eric Barret | Q115467896 | ||
| P2093 | author name string | Thomas J Polascik | |
| Hashim U Ahmed | |||
| Simon Bott | |||
| Jan van der Meulen | |||
| Behfar Ehdaie | |||
| Alec Miners | |||
| David Bottomley | |||
| Dean Barratt | |||
| Ian A Donaldson | |||
| Neil McCartan | |||
| Richard Hindley | |||
| Roberto Alonzi | |||
| Sarah Willis | |||
| Scott Eggener | |||
| Viktor Berge | |||
| P2860 | cites work | The index lesion and the origin of prostate cancer | Q84761775 |
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group | Q30054617 | ||
| Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study | Q30514532 | ||
| Focal therapy for prostate cancer: rationale and treatment opportunities | Q33702259 | ||
| Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy | Q33775669 | ||
| The role of focal therapy in the management of localised prostate cancer: a systematic review | Q34266167 | ||
| Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement | Q34288506 | ||
| Radical prostatectomy versus observation for localized prostate cancer | Q36194308 | ||
| Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer | Q36928846 | ||
| Prostate cancer screening and the management of clinically localized disease | Q37609671 | ||
| Focal therapy in prostate cancer-report from a consensus panel. | Q37755179 | ||
| Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer | Q38152243 | ||
| Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. | Q38180224 | ||
| Tracking the clonal origin of lethal prostate cancer | Q41762568 | ||
| Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? | Q43869254 | ||
| MR to ultrasound registration for image-guided prostate interventions | Q44229126 | ||
| Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. | Q46663012 | ||
| Can we deliver randomized trials of focal therapy in prostate cancer? | Q50243071 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate | Q9625 |
| Kallikrein related peptidase 3 | Q409450 | ||
| magnetic resonance imaging | Q161238 | ||
| consensus | Q202722 | ||
| prostate neoplasm | Q56014511 | ||
| P304 | page(s) | 771-777 | |
| P577 | publication date | 2014-10-01 | |
| 2015-04-01 | |||
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting | |
| P478 | volume | 67 |
| Q55232142 | "Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. |
| Q50085940 | 3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy |
| Q58794132 | A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer |
| Q42149311 | A method for mapping and quantifying whole organ diffusion-weighted image distortion in MR imaging of the prostate |
| Q36145325 | An update on focal therapy for prostate cancer |
| Q39177286 | Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology |
| Q30241244 | CCAFU french national guidelines 2016-2018 on prostate cancer |
| Q35941781 | Clinical impact of prostate biopsy undergrading in an academic and community setting |
| Q48296689 | Comparison of lesions detected and undetected by template-guided transperineal saturation prostate biopsy |
| Q89630679 | Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities |
| Q38436625 | Current trends and new frontiers in focal therapy for localized prostate cancer |
| Q40247297 | Development of a registration framework to validate MRI with histology for prostate focal therapy. |
| Q52916415 | Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy. |
| Q36049690 | Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States |
| Q50138465 | Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome |
| Q38808867 | Focal Therapy for Prostate Cancer: Pending Questions |
| Q41011798 | Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study. |
| Q38630336 | Focal irreversible electroporation as primary treatment for localized prostate cancer. |
| Q40440753 | Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control |
| Q30240753 | Focal therapy as primary treatment for localized prostate cancer: definition, needs and future |
| Q89686768 | Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI |
| Q50241890 | Focal therapy for prostate cancer: German version |
| Q41689116 | Focal therapy for prostate cancer: the technical challenges. |
| Q57297211 | Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey |
| Q50239157 | Focal therapy of prostate cancer |
| Q47100503 | Focal therapy will be the next step on prostate cancer management? | Opinion: Yes. |
| Q50239426 | High intensity focused ultrasound (HIFU) : Importance in the treatment of prostate cancer |
| Q26820469 | Histological outcomes after focal high-intensity focused ultrasound and cryotherapy |
| Q58784302 | Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments |
| Q35752671 | Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease |
| Q57122349 | Initial Experience of Targeted Focal Interstitial Laser Ablation of Prostate Cancer with MRI Guidance |
| Q90690736 | Intra- and interreader reproducibility of PI-RADSv2: A multireader study |
| Q33464674 | Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells |
| Q46872027 | MR-guided biopsy and focal therapy: new options for prostate cancer management |
| Q36173279 | MRI-guided focal therapy of prostate cancer |
| Q39191190 | Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach |
| Q39438297 | Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer |
| Q88313328 | Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed? |
| Q91855127 | New sparse implantation technique of I-125 low-dose-rate brachytherapy using concomitant short-term hormonal treatment for low and intermediate-risk prostate cancer: An initial study of therapeutic feasibility |
| Q58562122 | Optimizing patient selection for focal therapy-mapping and ablating the index lesion |
| Q30241856 | Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review |
| Q87729105 | Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer |
| Q88209404 | Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy |
| Q48302699 | Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop |
| Q39151621 | Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy |
| Q38871511 | Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project |
| Q89845717 | Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results |
| Q90808806 | Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications |
| Q64115030 | Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments |
| Q38963098 | Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer |
| Q38765817 | Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients |
| Q38739753 | Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. |
| Q63966178 | Surveillance after prostate focal therapy |
| Q50072616 | The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer |
| Q54996559 | The prostate cancer focal therapy. |
| Q59793110 | The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens |
| Q38745164 | Therapeutic Ultrasound and Prostate Cancer |
| Q33580964 | Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project |
| Q26750559 | Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight |
| Q57112886 | Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement |
| Q104517654 | [French ccAFU guidelines - update 2020-2022: prostate cancer] |
Search more.